Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study

Abstract

Older patients are underrepresented in early clinical trials with 17.7% of patients aged ≥70 years compared with the number of new cases of cancer in France (50%). However, when invited to participate, older patients were prone to sign informed consent.